These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 19440008)
1. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Novara G; Galfano A; Secco S; Ficarra V; Artibani W Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Shim M; Bang WJ; Oh CY; Lee YS; Cho JS Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133 [TBL] [Abstract][Full Text] [Related]
3. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. Bolton EM; Lynch T BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592 [TBL] [Abstract][Full Text] [Related]
4. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy. Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC; BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472 [TBL] [Abstract][Full Text] [Related]
13. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Hutson PR; Oettel K; Douglas J; Ritter M; Messing E; Staab MJ; Alberti D; Horvath D; Wilding G Cancer Chemother Pharmacol; 2008 Aug; 62(3):373-7. PubMed ID: 17922273 [TBL] [Abstract][Full Text] [Related]
14. How do we define "castration" in men on androgen deprivation therapy? Itty S; Getzenberg RH Asian J Androl; 2020; 22(5):441-446. PubMed ID: 31997782 [TBL] [Abstract][Full Text] [Related]
15. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743 [TBL] [Abstract][Full Text] [Related]
16. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B; N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183 [TBL] [Abstract][Full Text] [Related]